751
www.klinickafarmakologie.cz340804001076513320121425327329234035839843647950254457164568672477179183988990895196610061045
/26968040010732
Klin277380400107446583131
Farmakol2924804001074279105179220258305325
Farm.3269804001074178105179195
2025;39(1):22-333484804001074487128172185229271295335352367411455481521563
/40928040010731
KLINICKÁ4169804001074589109168189243289347
FARMAKOLOGIE4537804001074292139211266312372415475534555598
A51578040010752
FARMACIE5231804001074291138210265317337380
3356558020012657113
HLAVNÍ4945200012671127198263336370
TÉMA5337200012657114204274
Farmakokinetické306636001062867102157197233271307325366398432449484520552
lékové36343600106296197136173205
interakce38553600106155688120156198233266298
přímo41693600106336886139180
působících436536001063273105146182200234252286327
perorálních470836001063264100140176218249291308343384
antikoagulancií510736001063879112129165204242280321352394435469487504
67.343610085367281
Wen4446100835892131
HN,5966100834490103
He7206100834581
QF,822610083478187
Xiang930610083395487126165
XQ,1116610083398599
et12366100833557
al.1314610083324861
Predicting1396610083365792132148180205220259299
drug-drug1716610083386099138161202224263302
interactions343710083155375110131165197222238276315342
with706710083516790129
physiologically8567100833978109136152190207245285301333367383398430
based13077100833973100135175
pharmacokinetic/15037100833979111133192225258295327343382417440456488516
pharmacodynamic3438100833977109131189221254290330362401433491506538
modelling8968100835896136171186201216254293
and12048100833270109
optimal1329810083377799114172204219
dosing15648100833876103118155195
of17748100833756
apixaban18468100833271861171503439100833972110
and4739100833270109
rivaroxaban603910083203668101123160190223262295333
with957910083506688127
dronedarone1104910083385997135170210242263301339374
co-administration.1499910083316891123163220236274289315338359393414430468506519
Thromb3431010083337293130188228
Res.5861010083357097111
2022;218:24-34.71210100833468101136148183215246258293325348380416428
68.3431110085367389
Wang44811100835789127166
L,62911100833245
Shang69011100833371103141180
K,88611100833449
Feng95111100833266104143
T,111011100833342
et116711100833456
al.12391110083324760
LC-MS/MS13151110083317083139172198252285
Method161611100835490112150188228
Assay18601110083416895128159
for3431210083185678
Simultaneous43912100833348105143158181213252287325363390
Determination84812100834580102136157216231269301323338376415
of128212100833756
the13571210083226095
Apixaban14711210083418096127159199232270
and175912100833270109
Metformin1887121008355901123431310083185678136151189
in54613100831553
Rat6131310083356890
Plasma:7171310083355082108166198211
Assessment9421310083416995130157184241276314336
of129213100833757
Pharmacokinetic136313100833572105126184217249286316333371406428443475
Drug-185213100834667106145167
-Drug3431410083216788125163
Interaction5191410083145172105126158189213228265303
Study.8341410083325289128159168
J1015141008323
Chromatogr10511410083397696133190222243279318338
Sci.1401141008332647891
2023;61(6):522-529.15041410083346799133144179209223256273285319352386405439471504515
69.3431510085357083
Brings4371510083355570107144170
A,61815100834054
Lehmann68315100833164101157188225262
ML,9571510083538497
Foerster106515100833268103123149171204224
KI,13011510083345062
et137415100833455
al.14411510083314658
Perpetrator15101510083356787126160182202234255291311
effects18331510083335271104135158185
of34316100833756
ciclosporin412161008331467893131158197236257273310
(P-glycoprotein7351610083195475116131163194231270292329351384399437
inhibitor)11851610083155290105144160182219240258
and145616100833270109
its15781610083143764
combination165516100833168126165181219251272288325364
with3431710083516790129
fluconazole4931710083173472105143182215245283299334
(CYP3A8481710083195997134168209
inhibitor)10781710083145392107147163186223245264
on136317100833877
the14611710083216096
pharmacokinetics157817100833978111133192225258295326343382417343181008322376997
of46018100833757
rivaroxaban5371810083213669102123160190223262295333
in89118100831452
healthy96418100833772104120142180211
volunteers.11951810083326985123161182216252273300314
Br152918100833657
J1606181008324
Clin16511810083405570108
Pharmacol.177918100833573105126185217343191008331688497
2019;85(7):1528-1537.45519100833469100131143179213230265284296326356389423446476507540572578
70.3432010085367085
Wang44020100835788125164
Z,61620100833850
Chan67920100833977109146
EC.8382010083327285
Physiologically-Based93520100833572102129143180196234273287319351366381412434471503529564603
Pharmacokinetic155020100833572104124182214246282312328366400422437468
Modeling-Guided34321100835492130165180194232270292338375390428462501
Dose85621100834583109144
Management101221100835486123155193228285319357378
of140221100833756
Oral147021100834668100115
Anticoagulants159721100834178100114146182214253290305336374395422
when34322100835088122160
Initiating515221008315526789103135156171208247
Nirmatrelvir/Ritonavir7742210083445980137169190211245260292307328350386401423459497529560575596
(Paxlovid)13822210083195485116131169200215253273
for16672210083185576
COVID-19175622100833984119135180203233263
Treatment.3432310083335084116137196231269290304
Clin6622310083405570108
Pharmacol78523100833573105126185217249286302
Ther.110223100833372107128139
2022;112(4):803-807.125623100833468101136148178206236253286304316350386419441477512544551
71.3432410085367183
Nakagawa44624100834577107141180213263296
J,76324100832436
Kinjo8202410083345189104142
T,98324100833241
Ajuchi10452410083415694126164179
N,124524100834457
et132324100833456
al.14002410083324760
Effect14802410083335271106138163
of166324100833757
pregnane17402410083396195134172205243278
X343251008338
receptor3982510083205487121160182219241
and65525100833270109
cytochrome7802510083316590127159197218256314349
P450114525100833567100134
oxidoreductase12962510083376783122160181216255293325349382408443
gene175625100833873111146
polymorphisms19182510083397834326100831547105144165205243259285342369
on73026100833776
trough8242610083224381119158196
concentrations103826100833168107139173211232254287308324362400426
of148326100833757
rivaroxaban15582610083213669102123160190223262295333
and191026100833270109
edoxaban34327100833473112142175214247285
in64527100831553
patients7152710083387193108143181203230
with9632710083506688126
nonvalvular110627100833876115146179194227265281313334
atrial1457271008332547591123138
fibrillation.1612271008317347395110125141173195210248286299
Eur19292710083326990
J343281008324
Clin3822810083405671108
Pharmacol.50628100833572105126184217249286302314
2023;79(5):703-705.83628100833468101136147180213232266284296330363396418449482516528
72.3432910085367186
Attelind4452910083416185118133147184223
S,68329100833345
Hallberg7432910083447691105143178199236
P,99529100833539
Wadelius104929100835888127161176190227252
M,131729100835467
et140029100833355
al.14712910083314658
Genetic154529100834378116150171186217
determinants1778291008338729412714720521934330100833769106126153
of50830100833755
apixaban5743010083327085115147185217254
plasma8393010083395485111167199
levels10493010083154980114128153
and121430100833168107
their13323010083215993107127
relationship1471301008320536899120135172209234271285324
to180630100832157
bleeding187530100833853871223433110083375187124
and47731100833268105
thromboembolic5923110083215877112168206243276332369406420434464
events.10663110083346497133153179191
Front12673110083325085122142
Genet.141931100834377113146167178
2022;13:982955.16083110083336597129140169197207240273305337370400411
73.3433210085367287
Ueshima44632100834478105143158216248
S,71132100833345
Hira7733210083446081114
D,90432100834556
Fuji977321008332688499
R,109332100833549
et115932100833456
al.12323210083324760
Impact130932100831573112145177201
of152732100833757
ABCB1,160132100834177117153185193
ABCG2,181132100834177118160194207
and34333100833270109
CYP3A547133100834077113147187223
polymorphisms7133310083387793125183222243283322337363420447
on117933100833775
plasma12733310083395587114171204
trough14953310083224381119158196
concentrations1710331008331681061381722102322532863433410083223775113140
of49634100833857
apixaban5663410083327187118151190223261
in84034100831553
Japanese9073410083245695128166201228263
patients11833410083397294109144182203231
with14283410083506688126
atrial1568341008332547591123138
fibrillation.1720341008317337294110125140172194209247286299
Pharmacogenet34335100833573105126184217249286325360398433456
Genomics.81435100834479117156214229261289302
2017;27(9):329-336.113135100833569101130140175208224257274286322354388412444477512525
74.2138610085366883
Huppertz22356100834482121160195217241272
A,25206100834055
Grond-Ginsbach25876100834465103141180202248264302328367399431469
C,30696100834053
Dumschat31356100834583141167199237269291
C,34396100834052
et35046100833456
al.3573610083324760
Unexpected3646610083448111614821387100833873105129162201
excessive2352710083336495128154181195227261
apixaban2625710083327085116148187219257
exposure:28947100833465104142168205225259271
case3177710083316490124
report3314710083205492130152176
of35027100833756
a357171008331
patient3614710083397192107142179200
with2138810083506688126
polymorphisms2277810083397793125183222243283321336362420446
of27368100833756
multiple28058100835795110132147186202237
apixaban3055810083327186117150189222259
elimination3327810083345065122137175207229244282320
pathways.366081008339719313121389100835183114141155
BMC23089100833590131
Pharmacol24549100833673105126185217249286302
Toxicol.2772910083326696112144181197210
2019;20(1):53.29979100833468100130143178212232263278290325358370
75.21381010085367085
Wang223710100835789127166
L,241710100833145
Raghavan247610100833568107145177209242280
N,277010100834457
He284110100834479
K,293410100833550
et299810100833456
al.30681010083324760
Sulfation31421010083337085105138160175213251
of340710100833857
o-demethyl347810100833761101136194229251289320336
apixaban:21381110083327288119152192226264277
enzyme243611100833473102137196232
identification26891110083155489128150166184201233267289305343382
and309211100833271110
species322311100832766102135151186213
comparison.345711100833269128168202223239266304343357
Drug213812100834567105144
Metab229812100835489111144183
Dispos.24971210083456187126165191205
2009;37(4):802-808.271712100833468105140153188220236269286298333368401422458493528542
76.21381310085366985
Frost22361310083325289115138
CE,23861310083407386
Byon248413100833567104142
W,263913100835767
Song271813100833371109147
Y,287813100833543
et293413100833456
al.30021310083324760
Effect30741310083335270104137161
of324713100833756
ketoconazole33161310083306385122154191229261290327343377
and370613100833269108
diltiazem2138141008338526789104135164197254
on240514100833674
the24911410083225993
pharmacokinetics259714100833876107128185217249285315331368402424439470497
of310614100833756
apixaban,31741410083317085115147186218255268
an345414100833169
oral35351410083375890105
direct36521410083385373106139162
factor21381510083185284108145167
Xa232015100833870
inhibitor.24061510083145290105144160182219241251
Br267315100833556
J2745151008324
Clin27841510083405570108
Pharmacol.290715100833673105126185217249286302315
2015;79(5):323715100833569100131141174207227260279290
838-846.354315100833468102125161197233247
77.21381610085367281
Vakkalagadda22341610083366797128162177209249281320359391
B,264016100833548
Frost27031610083325289116139
C,285716100834053
Byon292516100833567105143
W,308316100835867
et316516100833457
al.32371610083314760
Effect33121610083325170104137161
of348816100833757
Rifampin35601610083355070103161200216254
on213817100833776
the22291710083216095
Pharmacokinetics233917100833572105126184217249286316333371406428443475503
of285717100833756
Apixaban,29291710083408095126159198231269282
an322617100833270
Oral331117100834769102117
Direct34431710083466182116149173
Inhibitor3631171008315539110614516121381810083225980
of223318100833857
Factor23051810083336294118155177
Xa.24971810083397184
Am259618100834199
J2711181008324
Cardiovasc27501810083407394132147185217250277309
Drugs.307418100834667106145171184
2016;16(2):119-127.327418100833468100131143173205224257275287317345375398429459492498
78.21381910085367187
Launay223819100833165102140172202
M,245319100835568
Demartin253419100834580138170191215230268
AL,28151910083417286
Ragey291419100833568106141172
SP,30991910083336772
et318419100833355
al.32521910083324760
Severe33251910083326799133154188
Inflammation,352619100831552708711917623426621382010083223775113126
Acute228120100834172110133167
Kidney24652010083345190128163194
Injury,26762010083155368106127161171
and286420100833169108
Drug-Drug298920100834667106145167214236274313
Interaction:33192010083155374108129162195219234272310322
Triple36582010083335066105121156
Penalty213821100833569108141156179213
for23722110083185778
Prolonged24712110083365794111149188228263303
Elimination27952110083334863122137175208230246284323
of313921100833857
Apixaban32172110083418197128162201235273
in351121100831553
Patients35852110083356890105140179201229
With21382210083577496134
Coronavirus22912210083407799136174207238254275313340
Disease26502210083456187122154180215
2019:288422100833469100131144
A3047221008341
Grand31072210083446598136175
Round.330122100833674112150189202
Ther352222100833372107128
Drug366922100834667106145
Monit.213823100835493131146169182
2021;43(4):455-458.233523100833569102133141176209227260277289323356389411447480514528
79.21382410085367083
Wang223424100835787125163
L,240924100833245
Zhang246624100833775106144182
D,266024100834556
Raghavan272824100833567105143174205238275
N,301524100834457
et308424100833456
al.31522410083314659
In322324100831552
vitro3287241008332476990127
assessment34262410083315783118144170227261299320
of375824100833756
metabolic213825100835691112144182220235250281
drug-drug24312510083375895133155194215252290
interaction27332510083145172105125158189212227264301
potential30462510083387697130167188203234249
of330725100833655
apixaban33742510083317085115147185217254
through36402510083215879115152213826100833875
cytochrome22262610083316488125157194215252310344
P45025832610083356699132
phenotyping,272826100833876111148186208241280296333371384
inhibition,31252610083145189104142158180195232270283
and342026100833269108
induction35402610083155291128160183198236274
studies.21382710083264987126141176203217
Drug237027100834567105144
Metab253027100835489111144183
Dispos.27292710083456187126164191205
2010;38(3):448-458.294927100833468100132144179214233266284296330367403426462495529543
80.21382810085367489
Tsuruya22492810083335593114153185219
Y,248928100833544
Nakanishi255328100834578109143181196223261277
T,285028100833342
Komori291328100833573132171193209
H,314328100834457
et322128100833457
al.32992810083324760
Different33802810083466282101136157192230252
Involvement36532810083155385123139213829100833369129166206229
of239129100833959
OAT247529100834890121
in262029100831655
Renal270029100833673113147164
Disposition28882910083476491132173201217241257297337
of325029100833959
Oral333429100834871106123
Anticoagulants34812910083438310612215619422927030921383010083154786107135
Rivaroxaban,22943010083365184117139176207240279313351364
Dabigatran,267830100834679118134173206227249282321334
and303230100833271110
Apixaban.31633010083418096127160200233272285
J3469301008324
Pharm351430100833573105127185
Sci.3720301008333658194
2017;106(9):2524-2534.213831100833468100129139169201236255288306318353388421453476507542575610623
81.21383210085367082
Vandell223432100833667105144179194210
AG,24573210083418397
Lee256732100833166101
J,268132100832436
Shi27313210083327085
M,282932100835568
et291032100833456
al.29803210083314760
An305332100834179
integrated31453210083155374108147169202223257297
pharmacokinetic/pharmacogenomic34553210083387710913018922125329032133721383310083377293108140167204241273294352383415451490525562600657672704
analysis285433100833269101116147174188214
of308033100833756
ABCB1314933100834075116151182
and334333100833269108
SLCO1B1346333100833263101145176208239
polymorphisms371533100833876213834100831547105144165205243259285342369
on252034100833775
edoxaban260834100833474112142175214247285
exposure.290634100833466105144171208229263275
Pharmacogenomics319434100833673105126185217249286326361399437495511543570
J.377734100832437
2018;18(1):153-159.213835100833468100131143173204223255269281311341374396427457489500
82.3934610085367186
Mendell40396100835589126165199214228
J,42866100832436
Zahir43416100833870107122142
H,45026100834456
Matsushima45776100835587108135172197234249306337
N,49336100834557
et50096100833456
al.5084610083324659
Drug-drug51626100834566104142164203224262300
interaction54816100831552731063934710083215587112127166205
studies4159710083275189129144180207
of43867100833858
cardiovascular4464710083326587126141179212245272305344359392413
drugs48977100833961100140166
involving5083710083155486124140173189227267
P-glycoprotein,53707100833658991141471792163934810083406199121156171210222
an41768100833372
efflux426881008335537190128160
transporter,4448810083224477116143182222243268303324334
on48028100833877
the4900810083226196
pharmacokinetics50168100834079112133193226258296327344382418440456488516
of55528100833858
edoxaban,39349100833473110140172210243280292
an42409100833269
oral4323910083375891105
factor4442910083195183106142163
Xa46199100833870
inhibitor.4703910083155289104142157179215236245
Am49629100834199
J507591008324
Cardiovasc5113910083407292130144181213245271302
Drugs.54299100834667104142168181
2013;13(5):331-342.39341010083346899128139168197215247265276311343373391423458490501
83.39341110085357185
Lenard403211100833164102133154191
A,423611100834054
Hermann43021110083437898156187225262
S,457611100833245
Stoll46331110083325289104119
F,476411100833237
et481411100833355
al.48811110083324759
Effect49521110083325170103135159
of512311100833756
Clarithromycin,51911110083395485106121143180201238295325356370407420
a3934121008332
Strong39781210083325374111149187
CYP3A417812100833976112145184
and437512100833169107
P-glycoprotein44951210083355595110142173209248269306327361376413
Inhibitor,49201210083155290105143159181217238248
on518012100833775
the52681210083215993
Pharmacokinetics53741210083357110312418221439341310083316797113150185207221253280
of422613100833756
Edoxaban429413100833370108137169208240278
in458413100831452
Healthy464813100834478109124146184214
Volunteers48741310083357186123160181215249270297
and518313100833269107
the53031310083215993
Evaluation5408131008333649611114818039341410083223775113
of406514100833756
the41381410083226095
Drug425014100834667106145
Interaction44121410083155374108129162194218234272310
with47391410083516789127
Other488314100834771109144165
Oral506614100834768101117
Factor52001410083326294118155177
Xa539414100833870
Inhibitors5481141008315539110639341510083395477114135162
by411215100833970
a4198151008332
Microdose424515100835570102123161200238265300
Cocktail456115100834077110140164197212227
Approach.480415100834180120141179212244282295
Cardiovasc51151510083407394132147185217250276309
Drugs543915100834667106145171
Ther.393416100833372107128138
2024;38(4):747-756.408816100833468101133145180214233266283295329359391410441474508521
84.39341710085367592
Gouin-Thibault404817100834484123139178202233273290330364403419442
I,451317100831428
Delavenne45631710083468399132165201240279315
X,490017100833953
Blanchard49751710083365386125158198231253292
A,529017100834156
et536817100833558
al.54481710083324962
Interindividual5533171008315543934181008322567894133173188222238278316349365
variability43191810083326587104136176193208224247282
in462118100831453
dabigatran469418100833871111127167200222244278317
and503118100833271110
rivaroxaban51611810083213771104126164195229268302341
exposure:552218100833466393419100834081110149172208222
contribution417919100833372112136159176218258283299340381
of458319100833859
ABCB1466519100834280123161195
genetic488319100833977117154178195229
polymorphisms51351910083408199133194235258300341358386446475
and393420100833271112
interaction40682010083155477112134168202227243283322
with44132010083516791131
clarithromycin.45662010083314881103120144183205244304336368385424438
J5026201008325
Thromb50732010083337396134194235
Haemost.533020100834478114174213241266280
2017;15(2):273-283.393421100833469101132142173204222257275288324357392415446481515529
85.39342210085367287
Garonzik40402210083447698135173203218248
S,430722100833346
Lim437222100833147104
ML,449622100835486100
Penzak461522100833569107136170200
SR,48342210083326781
et493522100833456
al.50102210083324760
The509022100833271106
Effects52162210083325170104137161189
of542422100833857
Clarithromycin550022100834055873934231008321365896117154212242274289326
on427323100833775
the43612310083215994
Pharmacokinetics446823100833572104125183215247284314330368402425440471499
of498023100833756
Apixaban50482310083418096126159198231268
in532923100831552
Healthy539423100834479110125148185216
Volunteers:39342410083367288125163185218254275302315
A4263241008341
Single-Sequence43182410083324785124139174197229264303341376414446479
Crossover48122410083396098124151189221255277
Study.51032410083325391130162172
Am528924100834199
J5402241008324
Cardiovasc54402410083407394132148393425100833769102129161
Drugs.411025100834667106145171184
2019;19(6):561-567.431025100833468100130143173203222255273285321355385404438472505511
86.39342610085367490
Zhang404626100833876109148188
D,425526100834657
Frost43342610083325391118142
CE,44982610083407387
He460726100834479
K,470826100833550
et478026100833457
al.48592610083314761
Investigating49422610083155385120148172188227260283299337377
the53412610083216096
Enteroenteric5459261008332719312739342710083215995134156190212229261
Recirculation421627100833671105120142174213229261284300339378
of461527100833757
Apixaban,46932710083418197129162202236275288
a5002271008332
Factor50552710083326295120158180
Xa525627100833871
Inhibitor:53482710083155492108148164187225247262
Administration393428100834180139154193209236259282315338354392431
of438528100833757
Activated44622810083417397113147180203237278
Charcoal475928100834078111133165203236252
to503128100832159
Bile51102810083355167102
Duct-Cannulated52322810083458411714216220623927831735539342910083154871106147
Rats41032910083366992121
and424629100833272112
Dogs438029100834686126154
Receiving455629100833572105140156190207246286
an486429100833272
Intravenous4958291008315547699133166201240280319346
Dose532729100834585113149
and549829100833272112
Use393430100834470106
of406230100833757
Drug414130100834568107147
Transporter43103010083325084123150190229251277311333
Knockout466530100833575114148179217256279
Rats.49663010083356991120134
Drug512230100834568107147
Metab529130100835490113147187
Dispos.54993010083466289393431100833978106120
2013;41(4):906-915.407131100833469101132144179210226260278290326363399423459492522535
87.39343210085367180
Stangier40353210083325486124163179213235
J,429032100832436
Stähle43473210083325386124139174
H,454232100834457
Rathgen46193210083356890128167202240
K,488032100833449
et495032100833456
al.50263210083324760
Pharmacokinetics510732100833572105126184217249286316333371406428443475503
and393433100833270109
pharmacodynamics406133100833978110131189222254291330362401433491506538566
of464633100833756
dabigatran472133100833870109125164196218239272310
etexilate,50503310083345690121137152184206240252
an532033100833270
oral54083310083385992108
direct55343310083385339343410083215689113
thrombin40683410083226182120179219235274
inhibitor,43623410083155492108148163186224246256
with46393410083516790129
coadministration478934100833169102142200216254270296320342375398413452491
of530134100833757
digoxin.53793410083395493132163179217231
J3934351008324
Clin39733510083405671108
Pharmacol.409735100833572105126184217249286302314
2012;52(2):243-250.442735100833468100130142177210228262280291327358391413444479513525
Připravujeme5715360037217428736854866282097311491234139216521811
do244953700356163322
Klinické57157100347172249323485558682832974
farmakologie16025710034795240344582728877103211081267143015041649
a330857100347148
farmacie351257100347962413445827288519271072
HLAVNÍ5996280012367117183239307334
TÉMA9546280012352104187251
–12266280012350
Nežádoucí12976280012367120165217276332389434460
účinky17786280012357102128185236289
imunosupresivní20886280012325110167224281322379438474525567593644702728
léčby2836628001232678124182232
PŘEHLEDOVÉ5996460012356112164232282333402473532584
ČLÁNKY12046460012358107173240299360
„599661008960
Antidepresiva7396590012161115146167222271327358406444466513560
v13176590012148
léčbě1383659001212473117172221
mateřské16226590012184130161209240279324371
deprese:20126590012156105160192240278327345
léčit2376659001212372116138169
nebo25636590012156105160215
neléčit?27966590012156104127176220241273309
„599674008960
Doplňky7396720012167121176199253298346
stravy1104672001213972103150195244
a13666720012148
onkologická14326720012155110155207230283338360403448496
léčba1946672001212473117172219
–21836720012150
před2251672001215789137192
čím2462672001214566148
musíme26286720012183137174196277326
pacienty29736720012156104147169217271302351
varovat?3342672001214895126179224271302338
„599687008960
Farmakologická739685001214992123205251297349371425480502545590638
léčba1395685001212472117171219
nejčastějších16326850012155104127170217255287335357394416459512
symptomů2163685001213986168224255308390443
v26246850012148
paliativní26916850012157104126147193224246293347369
péči30786850012157107151172
KAZUISTIKA5997040012358125184249276328381408467534
„599721008960
Farmakokinetické739719001214992123205251297349395418472521553574617662710
interakce1467719001212377108156187234279321369
klozapinu1854719001214770124164213268290344397
a22697190012148
olanzapinu:2335719001215578124178220268323345399452471
kazuistiky2824719001214794136190212249281303348397
lékových3239719001212372118170216265307361
změn36187190012143125174228
při3864719001215788110
inhibici3992719001212477131153208230273295
CYP1A243057190012158112165211264315
…a59974600121100150
spoustu769746001213890144197235267320
dalších11097460012153105129166189232286
zajímavých1415746001214294118142223276323371413467
témat…1902746001213277159212244342
2025249705360022693185274369498353900754344
▼506962300253143
VYCHÁZÍ48966440015566142216301381458489
V51076610015566
ČERVNU49156780015574138207278367452